Company intelligence / Profile preview

Neunco

New York, New York, United States

Ownership: Private
Employees: ~20
Development stage: Other

Overview

Neunco is a biotechnology company pioneering the field of neural-immune-oncology (NIO). The company focuses on the intersection of the nervous system, the immune system, and cancer to develop novel therapeutics. By targeting the neural regulation of tumor growth and immune evasion, Neunco aims to provide new treatment options for patients with difficult-to-treat cancers. The company is backed by Apple Tree Partners and is currently in the pre-clinical stage of development. Neunco's platform explores how neural signaling pathways can be modulated to enhance anti-tumor immune responses and inhibit tumor progression.

Therapeutic areas: Oncology
Modalities: Small moleculeMonoclonal antibody
Industry: Biotech

Beyond the preview

Go deeper on Neunco.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neunco.

Explore the full profile